Skip to content

Welcome to Discover Pharma! Today is : November 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FDA grants fast track to Nektar’s rezpegaldesleukin for severe alopecia areata

    Nektar Therapeutics has received FDA Fast Track designation for its [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    Centauri Therapeutics secures $5.1M from CARB-X to advance ABX-01 to first-in-human trials

    Centauri aims to start first-in-human clinical study for broad-spectrum immunotherapy [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden

    Acquisition enhances innovation offering and expands biotech footprint across Nordic [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    AI-powered bioreactor project aims to transform biologics manufacturing

    A Canada–UK collaboration is developing an AI-driven bioreactor platform designed [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Kling Bio and Sanofi collaborate to accelerate discovery of next-generation antiviral antibodies

    Biotech company Kling Bio has announced a new collaboration with [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Why immunotherapy sometimes fails: Study reveals unintended effects of antibody design

    A new study from researchers in Japan has uncovered a [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Manufacturing & Supply Chain

    Stevanato Group secures €200 million to support global capacity expansion for drug delivery solutions

    Stevanato Group has secured €200 million in financing to support [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Solvias expands US cGMP testing capabilities with RTP center phase 2 build-out

    Solvias has achieved Current Good Manufacturing Practice (cGMP) readiness at [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    Lonza upgrades CDMO outlook following strong H1 2025 performance

    Lonza has raised its full-year 2025 guidance for its contract [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    MSD strengthens commercial capabilities with commitment to Veeva Vault CRM ahead of major launches

    Global pharma leader MSD (Merck outside the US and Canada) [...]

    May 5, 2026
Previous232425Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Isomab data support safety of angiogenic approaches in coronary artery disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top